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Cyclic Vomiting Syndrome (CVS): is there a
difference based on onset of symptoms - pediatric
versus adult?
Nilay Kumar1, Qumseya Bashar2, Naveen Reddy3, Jyotirmoy Sengupta1, Ashwin Ananthakrishnan4,
Abigail Schroeder1, Walter J Hogan1 and Thangam Venkatesan1*
Abstract
Background: Cyclic Vomiting Syndrome (CVS) is a well-recognized functional gastrointestinal disorder in children
but its presentation is poorly understood in adults. Genetic differences in pediatric-onset (presentation before age
18) and adult-onset CVS have been reported recently but their clinical features and possible differences in response
to therapy have not been well studied.
Methods: This was a retrospective review of 101 CVS patients seen at the Medical College of Wisconsin between
2006 and 2008. Rome III criteria were utilized to make the diagnosis of CVS.
Results: Our study population comprised of 29(29%) pediatric-onset and 72 (71%) adult-onset CVS patients.
Pediatric-onset CVS patients were more likely to be female (86% vs. 57%, p = 0.005) and had a higher prevalence of
CVS plus (CVS + neurocognitive disorders) as compared to adult-onset CVS patients (14% vs. 3%, p = 0.05). There
was a longer delay in diagnosis (10 ± 7 years) in the pediatric-onset group when compared to (5 ± 7 years) adult-
onset CVS group (p = 0.001). Chronic opiate use was less frequent in the pediatric-onset group compared to adult-
onset patients (0% vs. 23%, p = 0.004). Aside from these differences, the two groups were similar with regards to
their clinical features and the time of onset of symptoms did not predict response to standard treatment. The
majority of patients (86%) responded to treatment with tricyclic antidepressants, anticonvulsants (topiramate),
coenzyme Q-10, and L-carnitine. Non-response to therapy was associated with coalescence of symptoms, chronic
opiate use and more severe disease as characterized by longer episodes, greater number of emergency department
visits in the year prior to presentation, presence of disability and non-compliance on univariate analysis. On
multivariate analysis, only compliance to therapy was associated with a response. (88% vs. 38%, Odds Ratio, OR 9.6;
95% Confidence Interval [CI], 1.18-77.05).
Conclusion: Despite reported genetic differences, the clinical features and response to standard therapy in
pediatric- and adult-onset CVS were mostly similar. Most patients (86%) responded to therapy and compliance was
the only factor associated with a response.
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Background
Cyclic vomiting syndrome (CVS) is a chronic gastro-
intestinal disorder that was initially described in children
but is now being recognized with increasing frequency
in adults [1-3]. Rome III criteria for CVS in adults
includes stereotypical episodes of vomiting regarding
onset (acute) and duration (less than 1 week); 3 or more
discrete episodes in the prior year and absence of nausea
and vomiting between the episodes [4]. Adult CVS can
range from mild disease with infrequent episodes to se-
vere life-disabling disease requiring multiple emergency
department (ED) visits and frequent hospitalizations
[1,5,6]. Since CVS is often unrecognized, these patients
often undergo a battery of unnecessary diagnostic and
therapeutic procedures without any clinical benefit [1,7].
Many patients, if not treated appropriately, develop co-
alescence of symptoms with interepisodic nausea and
loss of the periodicity of episodes. Several CVS patients
also undergo unnecessary surgical procedures such as
cholecystectomy for symptoms caused by CVS [7].
CVS may be categorized as pediatric- and adult-onset
CVS based on the age of onset of symptoms. Pediatric-
onset CVS patients develop symptoms prior to the age
of 18 while adult-onset CVS patients develop symp-
toms ≥ 18 years [1,8]. Genetic differences have been
identified in these two groups with mitochondrial DNA
(mtDNA) mutations, 16519 T and 3010A being asso-
ciated with pediatric-onset CVS [2,9-11].
Strong maternal inheritance of multiple disease mani-
festations and abnormal urine organic acids has been
demonstrated in children with CVS, suggesting the pres-
ence of predisposing mtDNA sequence polymorphisms
[12,13]. It has also been reported that pediatric-onset
CVS patients have a higher proportion of maternal in-
heritance of functional symptomatology as ascertained
by quantitative pedigree analysis [14].There are presently
no data that have elucidate the clinical differences and
response to treatment pertaining to these groups . Based
on our experience with a large cohort of CVS patients
seen at the adult CVS clinic in Milwaukee, we hypothe-
sized that despite these genetic differences, both groups
of patients had similar clinical characteristics and re-
sponse to standard medications used in the treatment of
CVS. For treatment of these patients we also utilized the
standard medical regimen shown to be effective in exist-
ing literature [15].
Aims
The primary aims of our study were 1) To define the
demographics and clinical characteristics and assess re-
sponse to therapy in pediatric-onset and adult-onset
CVS patients. 2) To identify predictors of response to
treatment in both groups of patients.
Results
Study population
Of 101 patients, there were 66 (65%) females. There
were 79 (79%) whites, 17(17%) blacks, 3 (3%) of hispanic
origin and 1 (1%) of other origin. Six patients met the
diagnostic criteria for CVS plus whereas 10 patients met
criteria for catamenial CVS (episodes triggered by men-
strual periods) [1]. CVS plus is defined as CVS in associ-
ation with neurocognitive disorders [16]. The mean age
at presentation was 27 ± 12.3 years. The median dur-
ation of an episode was 3 days (range 1-18 days) with 81
(81%) patients reporting a prodromal phase. At the ini-
tial clinic visit, 39 (39%) patients had coalescence of
symptoms with daily or near-daily symptoms but had
typical episodes at the outset. Patients with coalescent
CVS had a longer delay in diagnosis as compared to typ-
ical CVS patients (91 ± 86 vs. 75 ± 85 months) though
this was not statistically significant. Of all patients, 63
(62%) had abdominal pain as a prominent symptom dur-
ing episodes along with nausea and vomiting. The loca-
tion of the abdominal pain was variable with 40 patients
(63%) having generalized abdominal pain, 14 patients
(22%) reporting upper abdominal pain and 9 patients
(15%) with pain in the lower abdomen. Almost all
patients (90%) had nausea as a part of their symptom
complex and 76 patients (76%) stated that the onset of
episodes was in the morning. Data on hot and cold
showers was available in 73 patients; 38 (52%) patients
had symptom relief with hot showers and 1 patient had
relief with a cold shower. Hot showers were reported in
25/35 (71%) CVS patients using marijuana when com-
pared to non users 19/56 (34%, p = 0.01).
Triggers for CVS episodes were reported in 87(87%)
of patients with the most common triggers being nega-
tive stress (unpleasant or sad events) in 67(67%) and
positive stress (happy or exciting events) in 59(59%).
The recovery phase was very variable and ranged from
10 minutes – 7 days. Many patients had concomitant
co-morbid conditions such as anxiety (47%), depression
(49%) and dysautonomia (64%). Gastric emptying stud-
ies were available for review in 40 patients; 10 patients
(25%) had gastroparesis whereas 4 patients (10%) had
rapid gastric emptying and 26 (65%) had normal
emptying.
Thirty of seventy (43%) patients had a personal history
of migraine and 41/64(64%) had a family history of mi-
graine. Most of the patients in our cohort had under-
gone numerous diagnostic and therapeutic procedures;
28/92 (30%) had undergone a cholecystectomy for symp-
toms of CVS without any therapeutic benefit. Eighteen
of 75 patients (24%) reported some form of disability
from CVS. Sixteen (24%) of 66 patients had a delay in
higher education and 20 of 70 patients (29%) reported
job loss related to CVS episodes.
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Pediatric- vs. adult-onset CVS
In our cohort of 101 adults with CVS, twenty nine
patients (29 %) had pediatric-onset CVS as compared to
72 (71 %) with adult-onset CVS. The demographics,
clinical characteristics, associated co-morbid conditions
and response to treatment are depicted in table 1.
Patients were predominantly white in both groups but
more patients were female in those with pediatric-onset
CVS 25 (86 %) than adult-onset CVS 41(57 %),
(p = 0.005). Both subgroups had similar disease charac-
teristics with no significant differences noted in trigger
factors, co-morbid conditions, rate of surgery for CVS
symptoms, or personal/family history of migraine. Co-
alescence of symptoms was noted in both pediatric- and
adult-onset CVS. There were no significant differences
in response to treatment in both groups of patients
(p = 0.27).
Pediatric-onset CVS patients differed from adult-onset
CVS in having a higher prevalence of CVS-plus. (14% vs.
3%, p = 0.05). There was a marked delay in diagnosis in
both groups but those with pediatric-onset CVS has a
much longer mean delay in diagnosis in comparison to
adult- onset CVS (10 ± 7 vs. 5 ± 7 years, p = 0.001).
Adult-onset CVS patients had a significantly higher inci-
dence of tobacco and narcotic use of 46% and 23% when
compared to 12% and 0% in the pediatric-onset group
(p = 0.001 and 0.004 respectively).
Treatment profile of patients with CVS and variables
associated with response to treatment
Most patients 70/92 (76%) were on tricyclic antidepres-
sants (TCA) such as amitriptyline or nortriptyline, 18 /92
patients (20%) on topiramate and 27/92 (30%) on coen-
zyme Q-10, L-carnitine or riboflavin. Of the 77 patients
with adequate data on response to triptans as abortive
therapy, 64 (83%) patients were able to abort episodes.
Of the 70 patients on tricyclic antidepressants, 18
patients (26%) had to stop the medication due to drug in-
tolerance; the most common adverse effects included
bad dreams, behavioral changes and increased somno-
lence. The mean dose of TCA used in patients who toler-
ated therapy was 83.3 ± 36.6 mg. Adequate follow up
data was available in 76/101(75%) patients (75%) who
were initiated on medical therapy and mean duration of
follow-up was 11.2 ± 6.2 months. Response to treatment
in these patients is depicted in figure 1. The majority of
patients responded to treatment with 44 (58%) patients
having a complete response, 21(28%) a partial response
and 11(14%) patients with no response to therapy. There
were no significant differences in the type of medications
or dosages used in complete, partial and non-responders.
(Figure 2)
Table 1 Demographic and disease characteristics of
patients with CVS based on disease onset
Variables Pediatric Onset
(n-29),
Adult Onset
(n-72)
p-value
Mean age at onset
of symptoms(years)
13.4±12.5 32.3±12.3 0.0001
Female sex 25 (86%) 41 (57%) 0.005
Race (%)
White 25 (86%) 54 (75%) 0.29
Black 3 (10%) 14 (20%) 0.38
Hispanic 1 (4%) 2 (3%) 1
Other 0 1 (1%)
Type of CVS
CVS plus (%) 4 (14%) 2 (3%) 0.05
Catamenial CVS 5 (17%) 5 (7%) 0.15
Sato’s CVS 2 (7%) 4 (6%) 1
Delay in diagnosis
(months)
124.75±85.86 63.53±85.23 0.001
Coalescence 14 (48%) 25 (36%) 0.25
Associated Symptoms Available n = 27 Available n = 67
Abdominal Pain 16 (59%) 47 (70%) 0.34
Co-morbid disorders Available n = 28 Available n = 68
IBS 9 (32%) 18 (27%) 0.62
Anxiety 13 (46%) 32 (47%) 0.19
Depression 9 (32%) 33 (49%) 0.18
Bipolar Disorder 1 (4%) 1 (2%) 0.5
Migraine 16 (55%) 30 (43%) 0.28
Cholecystectomy 9 (32%) 19 (30%) 0.81
Family History (%) Available n = 25 Available n = 64
Family history of
migraine
16 (64%) 41 (64%) 1
Drug use % Available n = 27 Available n = 65
Marijuana 8 (30%) 27 (42%) 0.35
Alcohol 7 (26%) 10 (15%) 0.25
Tobacco 3 (12%) 30 (46%) 0.001
Narcotics 0 15 (23%) 0.004
Response to therapy 19/20 (95%) 47/56 (84%) 0.27
Figure 1 Response profile of CVS patients.
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The demographics and clinical characteristics of res-
ponders (both complete and partial) and non-responders
are depicted in table 2. On univariate analysis, non-
responders were more likely to have a pattern of coales-
cence (82% vs. 34% p = 0.005). They also had had longer
episodes lasting 6.5 days vs. 3.5 days and greater numbers
of ED visits (15 vs. 3) in the year prior to evaluation com-
pared to responders. The incidence of chronic opiate use
was significantly higher amongst non-responders than
responders (46% vs. 13%, p = 0.02). A significantly higher
rate of disability amongst non-responders was also noted
(57 % vs. 20 %, p = 0.05). Non-responders were less likely
to be compliant to treatment (38 % vs. 88 %, p = 0.004).
On multivariate analysis only compliance was found to
be statistically significant in predicting response to treat-
ment (p = 0.03, OR 9.6, 95 % CI 1.18-77.05).
Discussion
The salient findings of our study are that both adult-
and pediatric-onset CVS patients have a similar demo-
graphic profile and disease characteristics except that
pediatric-onset patients were more likely to be female
and had a higher prevalence of CVS-plus with concomi-
tant neurological disorders. This finding may be
explained by the genetic differences that have been eluci-
dated in previous studies [2,10,11]. The pediatric-onset
group also had a lower incidence of tobacco and opiate
use and a significantly longer delay in diagnosis of CVS.
This longer delay in diagnosis is an unexpected finding
given that CVS is fairly well-recognized condition in
children. It should be noted that though our center
attracts both children and adults with CVS, the majority
of the patients with pediatric-onset CVS were not transi-
tioned from the Children's Hospital of Wisconsin, which
is also a tertiary center for pediatric CVS. Dysautonomia
was diagnosed in 64 % of our CVS patients which we re-
cently reported to be a significant problem in this popu-
lation [17]. Similar to reported literature, CVS patients
in both groups had a strong personal or family history
of migraine [18,19]. Co-morbid conditions including
Figure 2 Medications used in complete, partial and non-responders did not reveal any significant differences.
Table 2 Univariate analysis of responders and
nonresponders to treatment
Variables Responders
[Partial n-21;
Complete n-44]
Non-Responders
(n-11)
p-value
Pediatric onset 31 18 0.49
Gender 63 64 1
Females %
Race
White % 82 82 1
Black % 14 18 0.66
Coalescence % 34 82 0.005
Narcotics % 13 45 0.02
Compliance % 88 38 0.004
Loss of job % 31 57 0.21
Disability % 20 57 0.05
Surgery for CVS % 29 30 1
No. of episodes/yr 31.3±50 46.6±52.8 0.4
Duration of episodes (days) 3.5±3.5 6.5±3.5 0.008
Warning phase (Minutes) 159.2±365 47.1±378.1 0.45
Recovery Phase (days) 1.7±1.9 2.2±1.9 0.43
No. of emesis/hr 12.2±17.1 19.1±17.4 0.31
ED visits last year 3.4±9 15.8±9.2 0.0002
Number of hospitalizations 11.5±31.8 31±32 0.08
Average duration
of hospitalizations
5.1±8.8 3.3±8.8 0.57
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anxiety, depression and irritable bowel syndrome were
seen in both groups and it is unclear if this is related
to the lack of receiving a credible diagnosis and the in-
ordinate delay in treatment that these patients experi-
ence. In addition, 30 % of patients underwent invasive
surgery for CVS symptoms without any benefit. Long
delays in diagnosis along with such unnecessary and
unhelpful interventions are unacceptable both from a
patient standpoint and from an economic perspective.
The majority of our patients (86 %) had either a
complete or partial response to prophylactic medica-
tions with TCA’s, topiramate and mitochondrial therapy
such as carnitine, coenzyme Q-10 and ribofavin. The
dose of carnitine used was 1 gram twice daily, co-enzyme
Q-10 was 200 mg twice daily and riboflavin 100 mg once
daily. On univariate analysis, non-response to therapy
was associated with coalescence of symptoms, chronic
opiate use and more severe disease as characterized by
longer episodes, greater number of ED visits in the year
prior to presentation, presence of disability and non-
compliance. Compliance was the only significant variable
on multivariate analysis that predicted response to ther-
apy. Patients were deemed noncompliant if they contin-
ued to use marijuana and it is the practice of the author
to advise complete abstinence from marijuana in all
patients. We did not routinely check for cessation of
marijuana in our patients with toxicology screens. There
was no difference in response to therapy between
pediatric-onset and adult-onset CVS patients despite re-
cent reports of genetic differences. This may imply that
there are other factors involved in the pathogenesis of
this disorder aside from mitochondrial abnormalities
in adults.
The few patients who were administered TCA’s prior
to being seen at our clinic were on a low daily dose of
25 mg that is employed in other functional gastrointes-
tinal disorders. Dose escalation to 1 mg/kg as used in
children produced the desired therapeutic effect. How-
ever, there was a high incidence of side effects associated
with TCA therapy resulting in discontinuation in 26% of
patients which limited its use [20].
Marijuana use was seen in more than a third of
patients with CVS and patients frequently reported
using this for alleviation of nausea and as an appetite
stimulant. There did not appear to be any clear cause-
and-effect or temporal relationship between the use of
marijuana and onset of symptoms based on clinical his-
tory and these patients were not thought to have symp-
toms caused by the use of marijuana. Marijuana use has
been thought to result in cannabinoid hyperemesis [21-
23]. Though the patients reported in the literature have
not had adequate follow up; this entity as a separate dis-
order is subject to controversy. This raises questions
about whether chronic marijuana use down regulates
CB1 receptors and paradoxically causes more nausea
and vomiting which will need to be evaluated in the fu-
ture studies.
We acknowledge that there are several limitations to
this study as this was a retrospective analysis though the
data was also obtained prospectively with a standardized
questionnaire used in clinic. The response to medica-
tions has been arbitrary in CVS thus far and there has
been no consensus or accepted definitions in adult
patients for measures of response to treatment in CVS.
ED utilization has been recently studied in CVS patients;
we used overall improvement of symptom frequency and
severity to assess response to treatment [24]. We were
unable to report on exact numbers of ED visits prior to
and after treatment as many patients visited other ED’s
for CVS episodes. In addition while other authors have
measured ED visits and hospitalizations as outcomes of
therapy, some patients with CVS have home intravenous
fluid therapy or are seen in infusion clinics as in our
practice to help control their symptoms and avoid long
waits in the ED and prevent hospitalizations. Our study
is one of the largest studies characterizing adult-onset
and pediatric-onset CVS patients. This study should
pave the way for future prospective evaluation of treat-
ment in patients with CVS and standardized measures
of disease outcomes.
Conclusion
In conclusion, adult-onset CVS patients have similar
symptoms to those with pediatric- onset CVS and have
similar rates of response to therapy. CVS patients appear
to respond favorably to higher doses of TCA’s of 1 mg/kg
in comparison to the lower doses that are used in other
functional gastrointestinal disorders. CVS is associated
with an enormous psychosocial and economic burden
and patients must be diagnosed early and treated with
appropriate medications. Combination of medical and
behavioral therapy based on a bio-psycho-social model is
key to successfully treating patients.
Methods
Study population
A retrospective review of 101 adults with CVS seen at
the Medical College of Wisconsin between September
2006 and October 2008 was performed. The adult CVS
clinic at the Medical College of Wisconsin (MCW)
serves as a tertiary referral center for patients with CVS.
Patients were identified based on the Rome III criteria
for CVS and comprised of patients from 15 states in the
USA and Canada. Data was collected at the time of ini-
tial patient visit and subsequent follow up visits. All
patients had stereotypical episodes at onset but some
patients developed coalescence of symptoms later when
they developed significant interepisodic nausea and
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dyspepsia and lost the typical periodicity seen during the
initial phase of their illness. Patients with coalescence of
symptoms were included only if they had episodic symp-
toms at the outset.
Data collection
Demographic characteristics including age, gender, race,
geographic location, personal and family history of all
patients were collected at the time of initial evaluation
with a standard questionnaire that was completed by
patients prior to their appointment. This was then
reviewed at the time of the initial clinic visit and infor-
mation was confirmed. Data was collected on disease
characteristics such as duration and severity of disease,
age of onset, delay in diagnosis, specific triggers, asso-
ciated co-morbid conditions, history of marijuana use
and number of emergency department (ED) visits and
hospitalizations. Medications used as prophylactic ther-
apy in CVS including tricyclic antidepressants such as
amitriptyline and nortriptyline, anti-epileptics such as
topiramate and mitochondrial supplements such as co-
enzyme Q-10, L-carnitine, and riboflavin were recorded.
Adverse effects of medications, response to treatment,
disability and job loss due to CVS were ascertained. Data
was collected on a Microsoft Excel spreadsheet; most of
the variables were in a categorical format with some data
such as number of ED visits and hospitalizations
recorded as continuous variables. Data was collected as
per the historical recollection of the patient with supple-
mentation from previous medical records. The patients
were divided based on time of onset of symptoms
(pediatric-onset and adult-onset) and response to ther-
apy [1]. This study was approved by Institutional Review
Board at the Medical College of Wisconsin.
All patients seen in our clinic were asked standard
questions about the frequency, duration and severity of
episodes. Complete response to therapy was defined as
≥ 80 % amelioration in symptom duration, frequency
and severity and partial response was at least a 50-80 %
reduction. Non-responders had either no change in their
disease status or < 50 % reduction in symptom duration,
frequency and severity. Patients were deemed compliant
if they reported taking their prescribed medications and
either discontinued or reduced their marijuana intake
significantly. Cessation of marijuana use was not verified
routinely with a drug screen.
Data analysis
The data was analyzed using the Stata (StataCorp, Col-
lege Station, TX). Categorical variables were summarized
using proportions while continuous variables were sum-
marized using means and standard deviation. The Fish-
er’s exact test or the chi-square test was used to perform
between-group comparisons of categorical variables. The
t-test was used for comparing continuous variables.
Univariate logistic regression was performed to identify
variables associated with the dichotomous outcomes of
interest, namely pediatric onset disease and response
(complete / partial response vs. non-response) to therapy.
Linear regression was used for continuous outcomes in-
cluding number of hospitalizations, ED visits, duration of
episodes and number of episodes. Variables that were sig-
nificant in these regression models at p< 0.1 were
selected for inclusion in the final multivariate model
where p< 0.05 was indicative of independent statistical
significance.
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